The WhiteOak Group, Inc.
Breakthrough Nucleic Acid Therapeutics by QTsomeTM Technology.
Advances in medical technology and our understanding of biology have paved the way for the treatment diseases once thought incurable. Delivery of drug to the correct site of therapeutic action while minimizing off-target exposure is paramount to achieving safe and effective therapy. WGI overcomes delivery challenges in complex diseases including oncology through strategic application of nanotechnology.
Who We Are
The Leading Biotechnology Startup
We’re a young and talented group of entrepreneurs and scientists with a groundbreaking idea designed to contribute towards a better quality of life for patients. To transfer ideas to real product, we provide innovative solutions by collaborating and utilizing top academic and industry resources.
At The WhiteOak Group, Inc., we believe that the right understanding and technological edge can lead companies towards a successful future.
Contact us today to set up a meeting if you are interested in potential cooperation or investment.
QTsome has been demonstrated in several cancer models as an effective vehicle for drug delivery, with the potential to greatly augment the potency and safety profile of many anti-cancer drugs.
Quaternary-Tertiary Lipoamine Lipid Nanoparticles (QTsomes) are being developed as an innovative nanoscale gene delivery platform with broad spectrum application, superior efficiency, and improved safety relative to several competitive delivery strategies.